ArticleJournal of cardiothoracic surgery2026
miR-92a as a potential biomarker and therapeutic target in heart failure: evidence from human and mouse studies.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis research investigated the expression of microRNA-92a (miR-92a) in chronic heart failure (CHF) patients and assessed its regulatory mechanism using a transverse aortic constriction (TAC) mouse model.
methodsThirty patients with CHF (NYHA class II-IV) and 30 age and sex-matched healthy controls were enrolled from January 2021 to April 2022. Plasma levels of miR-92a were analyzed by quantitative reverse transcription polymerase chain reaction (qRT-PCR). In addition, we utilized the TAC heart failure mouse model (n = 12) to evaluate the change in cardiac function following adeno-associated virus (AAV) mediated inhibition or overexpression of miR-92a. The following echocardiographic variables were evaluated: ejection fraction (EF), fractional shortening (FS), left ventricular internal diameter diastole (LVIDd), and left ventricular internal diameter systole (LVIDs).
resultsmiR-92a levels were significantly increased in CHF patients and mice following tac application (p < 0.01). Inhibition of miR-92a expression improved cardiac function as evidenced by increased EF and FSs, and decreased LVIDd and LVIDs (p < 0.05).
conclusionmiR-92a may serve as a novel diagnostic and therapeutic biomarker for heart failure by altering cardiac remodeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.